| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8739711 | Journal of Clinical Virology | 2018 | 4 Pages |
Abstract
Resistance detected in proviral DNA, together with a low nadir CD4 count and a short previous virological control, predicts VR after therapy switching in virologically suppressed patients. PBMC GRT can be a useful tool for tailoring treatment switch, especially if paired with information about previous cumulative resistance and previous viro-immunological history.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Daniele Armenia, Mauro Zaccarelli, Vanni Borghi, William Gennari, Domenico Di Carlo, Alberto Giannetti, Federica Forbici, Ada Bertoli, Caterina Gori, Lavinia Fabeni, Carmela Pinnetti, Raffaella Marocco, Alessandra Latini,